Starpharma
(ASX:SPL) says their next internal development candidate, DEP® gemcitabine significantly enhanced anti-tumour activity compared with Gemzar® both alone and in combination with Abraxane® in a preclinical human pancreatic cancer model.
This data has formed the basis of a new patent application, which will provide coverage over DEP® gemcitabine to 2040.
DEP® gemcitabine is a DEP® version of Lilly’s Gemzar® (gemcitabine) - a well-established anti-cancer drug, which had peak sales of US$1.7 billion.
Gemzar® (gemcitabine) is one of the leading chemotherapeutic drugs used to treat pancreatic cancer.
Shares in Starpharma
(ASX:SPL) last traded at $1.16.
